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Phosphate binders on iron basis: A new perspective? Uremic weekly dialysis approximately 100 mmol per week are
patients on maintenance hemodialysis are in positive phosphate eliminated. This amount is considerably less than the
balance. This is mainly the result of the complex elimination cumulative net weekly adsorption of P in the anurickinetics of phosphate during dialysis. Removal of phosphate
patient [5], so there is a clear need to prevent intestinalis less than net dietary intake. Classical phosphate binders such
absorption of P so as to achieve neutral P balance.as calcium carbonate, calcium acetate, and aluminum-based
compounds are limited by side effects (hypercalcemia) and
outright toxicity (aluminium). There have been numerous re-
cent attempts to develop alternative phosphate binders, e.g., ELIMINATION KINETICS OF PHOSPHORUS
polyallylamine-hydrochloride (Renagel), lanthanum carbon- DURING DIALYSIS
ate, and trivalent iron-containing compounds. The latter is
Although as a first approximation the elimination ofbased on old observations that iron salts may cause hyperphos-
urea follows first-order reaction consistent with uniformphatemia and rickets in experimental animals and in patients.
This idea has recently been taken up again, and effective inhibi- distribution in a single compartment, elimination kinetics
tion of net intestinal phosphate uptake in non-uremic and ure- of P are more complex. Hou et al. [4] as well as previous
mic rats has been shown using simple iron salts (citrate, chlo-
investigators [6, 7] found a rapid initial decrease of serumride, ammonium citrate) and complex compounds (cross-linked
P concentration during a dialysis session; as soon as thedextran and stabilized polynuclear iron hydroxide). In uremic
rats, the latter compound reduces urinary phosphate excretion normal range of serum P concentration was reached,
as an indicator of reduced intestinal phosphate uptake and has however, the serum P concentration tended to remain
also been shown to be effective in subjects with preterminal constant independent of blood flow [7]. The major pro-
renal failure. So far, no side effects or short-term toxicity has
portion of P was eliminated during the first hour. Con-been observed. The compound appears promising and deserves
versely, upon termination of hemodialysis, a rapid re-further evaluation.
bound occurred, and within 12 hr approximately 80%
of predialysis serum P values were reached [6, 7]. The
explanation is that P is sequestered in deep compart-Hyperphosphatemia continues to be a challenge for
ments; the transfer rate constants from the intracellularthe clinical nephrologist. Control of serum phosphate con-
centration is a central strategy in the treatment of second- into the extracellular space are small, so that the rate of
ary hyperparathyroidism, but it is also important in view P exit from intracellular space can no longer keep pace
of recently recognized cardiovascular hazards of hyper- with the rate of removal through dialysis and becomes
phosphatemia [1]. rate-limiting. That redistribution of P is indeed the bot-
The mass balance of phosphorus (P) is precarious in tleneck of P elimination has been nicely illustrated by
the uremic patient on dialysis treatment. A normal West- recent observations [8] showing that more frequent long
ern diet contains approximately 800–1500 mg of P per dialysis sessions, i.e., 6 instead of 3 times per week, per-
day [2], of which 50–70% are absorbed in the intestine. mit elimination of substantial amounts of P, so that,
It is still uncertain whether the net P intestinal absorption paradoxically, even addition of P to the dialysate is neces-
is less in the uremic patient compared to controls [3], sary in some patients to prevent P depletion [9].
but if some intestinal malabsorption of P exists, it does
Classical phosphate bindersnot have a major impact on prevention. According to
Hou et al. [4], during a 4-hour hemodialysis session using Very early on, this dilemma forced clinical nephrolo-
1.0 m2 cellulose acetate hollow fiber dialyzers, approxi- gists to use phosphate binders in order to sequester P in
mately 33 mmol P are removed, so that with thrice the intestinal tract and to reduce entry of P into the
extracellular fluid space. Historically, calcium carbonate
and subsequently calcium acetate had been used mostKey words: hyperphosphatemia, renal failure, phosphate binders, iron,
hemodialysis. frequently. They are undoubtedly effective, but more
recently, with more successful management of hyper- 1999 by the International Society of Nephrology
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parathyroidism and a tendency for PTH (and in parallel linked iron dextran, i.e., iron (III)oxide-hydroxide-modi-
fied dextran [26], as an oral phosphate binder in the rat.bone turnover) to be lower, the risk of hypercalcemia on
oral calcium-containing phosphate binders has increased This was based on phosphate-binding studies in aqueous
solutions and whole blood [27], which had shown re-[10]. Although reducing the dialysate calcium concentra-
tions diminishes the risk of hypercalcemia, Argiles et markable P binding efficacy. Binding was pH-dependent
and maximal at pH 2–3, but when passage of the phos-al. [11] showed that, in the long run, dialysate calcium
concentrations below 6 mg/dl (1.5 mm) are not safe: they phate binders through the intestine was simulated in
vitro by varying the pH over 6 hours, net binding capacitymay cause stimulation of the parathyroid gland and loss
of bone mineral, particularly if patients are noncompliant was still substantial and reduced only modestly com-
pared to pH 2. Iron (III)oxide-hydroxide dextran beadswith the intake of calcium-containing phosphate binders,
so that the calcium balance becomes negative. were exposed to chick duodenum to assess whether Fe
was mobilized from the compound. Enzymatic iron liber-Aluminum-containing phosphate binders expose the
uremic patient to the hazard of aluminum intoxication ation was very limited at best. In vivo studies with rats
showed that, while plasma phosphate concentrations re-[12]. In an ideal world, aluminum-containing phosphate
binders should be avoided completely, but, unfortunately, mained virtually unchanged when rats were fed with
phosphate binder-containing food, the amount of P ex-one is often forced to use some when the use of calcium-
containing P binders leads to hypercalcemia [10]. creted in the urine was lowered by a factor of 15. It was
concluded that 1 g of this P binder will bind approxi-
Novel phosphate binders mately 0.65 mm of P. If one extrapolates to a 70 kg human
being, approximately 15 g/day of the binder would beThe dilemma of side effects (hypercalcemia with cal-
cium-containing P binders) or toxicity (aluminum-con- necessary. No animal died in the study by Spengler et
al. [25], animals grew and toxicity studies, including nec-taining P binders) led to efforts to develop alternative P
binders. One compound, polyallylamine-hydrochloride ropsy after 8 weeks of exposure, failed to reveal any
evidence of subacute toxicity. Using an organic ferric(Renagelt) has been intensively investigated in experi-
mental and clinical [13–15] studies. This class of com- compound, Hsu et al. [28], possibly unaware of this pre-
ceding study, fed ferric ammonium citrate and ferricpounds was originally developed to lower plasma lipids,
and this effect is still seen with Renagel as well. Polyal- chloride to normal and azotemic rats. They were on a
1.02% P diet to which the ferric salts had been added.lylamine-hydrochloride was shown to lower predialytic
plasma P concentrations from 2.93 mm to 2.13 mm in a Urinary P excretion was consistently lowered. Since in-
take was unchanged, obviously net intestinal absorptionshort-term study, and similar effectiveness was also noted
in long-term studies at a maximum daily dose of 5.5 g. had been lowered. The authors calculated that the bind-
ing capacity was 88–181 mg of P per g of elemental iron.It is apparently somewhat difficult to lower P levels, as
desired, in the mid-normal range, at least when this P Two recent observations point to the potential use-
fulness of these compounds in humans. We [29] exam-binder is used as monotherapy.
Another approach is the development of lanthanum- ined 13 patients with stable preterminal renal failure
(median serum creatinine 5.4 mg/dl). The patients werebased compounds. Lanthanum-chloride-hydrate was stud-
ied in animal experiments [16], and little tissue uptake hyperphosphatemic (median fasting plasma P 2.2 mm)
on stable dietary P intake. After two weeks on no oraland toxicity was noted. A clinical study using lanthanum
carbonate is currently underway, but the results are not P binders, 3 3 2.5 g stabilized polynuclear iron hydroxyde
was given with meals for 4 weeks—a deliberately subop-available.
A third line of products concerns trivalent iron salts. timal dose. This dose caused a median decrease of fasting
plasma P of 20%. Urinary P excretion was lowered evenThe available information on this interesting group of
compounds will be discussed below. more, i.e., by 37%. Apart from a certain laxative action
and black discoloration of feces, no side effects were
Fe-III based phosphate binders noted in this short-term study. Figure 1 shows the individ-
ual changes in plasma phosphate and urinary P excretionSeveral anecdotal clinical observations [17, 18] docu-
ment that ferric compounds bind dietary phosphate and rate. Of note, no significant changes in serum iron and
serum ferritin were noted. In a preliminary study, Changlower serum phosphate when given orally and even intra-
venously [19]. Iron salts have been shown to reduce bone et al. [30] investigated 32 dialyzed uremic patients who
were treated either with conventional phosphate bindersash in Guinea pigs [20], to retard growth and induce phos-
phate depletion in rats [21, 22], and to cause phosphate- (calcium carbonate and/or aluminum-containing com-
pounds) or a non-ionic ferric polymaltose complex (Fer-deficiency rickets in chicken [23] as well as in swine [24].
This line of observation lay dormant for a long time, rumt chewable tablet, Hausmann Laboratories, Switzer-
land) containing 1.78 mmol elemental iron per tablet.but recently has been independently taken up by several
groups of investigators. Spengler et al. [25] studied cross- After wash-out of the P binders, plasma P was 2.64 and
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Fig. 1. Percent decrease of plasma phosphate
(A) and urinary phosphate excretion (B) in 13
patients with stable preterminal failure at days
14 and 28, respectively.
2.53 mm in the two groups, which subsequently received the substance [29]. Further details are currently being
assessed in a randomized prospective controlled studyconventional P binders again or Ferrum tablets, respec-
in dialyzed patients. A potential advantage of these com-tively. Ferrum was less effective than conventional P
pounds is the favorable relation between cost and effec-binders. A mean decrease of 0.38 mm P was seen after
tiveness.8 weeks compared with 0.85 mm in controls, but at least
Whether the combination of P binders and inhibitorsproof of principle is provided by this preliminary obser-
of the intestinal Na,P-transporter [31] is a useful strategyvation. There was no significant change in ionized cal-
will require further studies. Available substances, e.g.cium, ferritin, serum iron, or iron saturation.
Niceritorol [31], are not free of side effects, but it is
not excluded that in the future, non-absorbable specific
SUMMARY inhibitors with no systemic side effects can be developed.
Various Fe(III) compounds are effective and presum-
Reprint requests to Professor Eberhard Ritz, Department of Internal
ably safe P binders. Further information is required with Medicine, University of Heidelberg, Bergheimer Straße 56a, D-69115
Heidelberg, Germany.respect to absorption of iron (which may be a benefit
in disguise in the age of erythropoietin treatment) and
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